Prestige Buys $1B OTC Brands from Foundation

Prestige Consumer Healthcare Inc. is set to significantly bolster its market position with the acquisition of a substantial portfolio of over-the-counter health and wellness brands from Foundation Consumer Healthcare. The transaction, valued at an enterprise worth of $1.045 billion, marks a strategic shift for both entities within the dynamic consumer health sector. This substantial deal is anticipated to finalize in the initial half of fiscal year 2027, pending customary regulatory approvals.

The divested collection encompasses a range of well-recognized brands, including the prominent Breathe Right nasal strips, Children's Dimetapp cough and cold remedies, and Anbesol oral pain relief products. The portfolio also features seven other established OTC brands: Alavert, Dristan, Primatene Tablets, FiberCon, Campho-Phenique, St. Joseph Low Dose Aspirin, and Bronkaid. These brands collectively generate approximately $200 million in annual revenue and contribute roughly $95 million in EBITDA, underscoring their significant commercial value.

For Foundation Consumer Healthcare, this divestiture represents a deliberate strategic pivot. The company, backed by private equity firms Kelso & Company and Juggernaut Capital Partners, intends to concentrate its resources and efforts on expanding its Women's Health division. This focus is anchored by its leading emergency contraception brand, Plan B One-Step, which has maintained an over-the-counter status without age restrictions since 2013 and holds the distinction of being the number-one OB/GYN recommended brand in its category within the United States.

Greg Bradley, CEO of Foundation Consumer Healthcare, articulated the rationale behind the strategic realignment. "Our decision to concentrate on women's health is a deliberate move to unlock further company value," Bradley stated. "This allows us to pursue new collaborations and initiatives that will accelerate our expansion within the women's health market." This move aligns with a broader trend of specialization within the healthcare industry, where companies seek to maximize returns by honing in on core competencies and high-growth segments.

The acquisition is a significant expansion for Prestige Consumer Healthcare, a public entity known for its strategy of acquiring and managing a diverse array of consumer health brands. The integration of Breathe Right and the associated product lines will substantially enhance Prestige's footprint in critical categories such as cough and cold, respiratory care, and oral hygiene. The consumer healthcare market, particularly the OTC segment, continues to demonstrate resilience and growth, driven by an aging population, increased consumer focus on self-care, and innovation in product development. The global OTC market is projected to see continued expansion, with specific segments like respiratory and pain relief showing robust demand.

Canaccord Genuity provided exclusive financial advisory services to Foundation Consumer Healthcare throughout this significant transaction. The deal's structure and valuation reflect the strong performance and brand equity of the divested assets, as well as the strategic importance of the women's health sector for Foundation Consumer Healthcare. This transaction is a notable example of portfolio optimization within the private equity-backed consumer health space, enabling focused growth strategies for both the seller and the acquirer.